External Research Grants
Myasthenia Gravis Rare Disease Network
The Myasthenia Gravis Rare Disease Network, MGNet, part of the National Institutes of Health's Rare Diseases Clinical Research Network, has two funding opportunities available this year. Applications for both are due October 1, 2023.
Myasthenia Gravis Network (MGNet) Scholar Program
Pilot Grant Program for Myasthenia Gravis
Scholar Program: $78,000
The Scholar Program provides up to 2 years of support for mentored research training to prepare Scholars for an independent research career in the field of Myasthenia Gravis. Selected Scholars receive up to $75,000 per year and an additional $3,000 per year to travel to MGNet sites for training and or to attend scientific meetings.
Application is due October 1, 2023 5PM EST
APPLY NOW
Scholar Awards | The Myasthenia Gravis Rare Disease Network (rarediseasesnetwork.org)
Pilot Program: $75,000
The Pilot Grant Program will provide up to two years of funding $75,000 per year to support clinical research dedicated to myasthenia gravis. We are seeking proposals for highly innovative investigations in early stages of development focused on clinical research, including fulfilling the definition of clinical research and exclusion of animal studies.
Application is due October 1, 2023 5PM EST.
APPLY NOW
Pilot and Feasibility Grants | The Myasthenia Gravis Rare Disease Network (rarediseasesnetwork.org)
MGFA Funding Opportunities
Clinician and scientist investigators are engaged in groundbreaking myasthenia research all over the world. MGFA funds promising research studies and clinical trials to discover potential new treatments and methods of living a better quality of life with MG.
Nancy Law High Impact Award
The request for a letter of intent for the spring 2023 grant cycle is now closed. Those invited to submit a proposal were notified.
For those invited to submit a proposal: All components must be submitted via MGFA’s grants portal, ProposalCentral, by September 8, 2023. You must create an account and log in to view the information. The appropriate forms will be found by searching for Myasthenia Gravis Foundation of American under “Grant Opportunities.” Proposals will be reviewed by the MGFA research committee as well as ad hoc reviewers when required; NIH scoring scale and categories will be used.
Please reach out with any questions.
This award was created in honor of Nancy Law, the former CEO and board chair of the Myasthenia Gravis Foundation of America. Her dedication to supporting people with MG inspired this research funding award opportunity. Professionals conducting research that will ultimately improve the lives of people with myasthenia gravis and related neuromuscular junction disorders are invited to apply. MGFA funds highly meritorious projects with a maximum total cost of $100,000 per year, for a period of 3 years.
Established and new independent investigators with faculty status are eligible to apply. This RFA is not open to for-profit (i.e. biotechnology and pharmaceutical) applicants. Applications in all areas of MG research will be accepted from U.S. and international applicants.
More details about this grant are available in the Research Funding Announcement document.
KEY DATES
Activity |
Date |
Research Funding Announcement |
April 14, 2023 |
Letter of Intent Deadline |
June 12, 2023 |
Application Deadline |
Sept. 8, 2023 |
Funding Notification |
Oct. 30, 2023 |
Funding Provided |
Nov. 2023 |
Annual Report Due |
Nov. 2024; Nov. 2025 |
Final Report Due |
Feb. 1, 2027 |
High Impact Pilot Project Award
The request for a letter of intent for the spring 2023 grant cycle is now closed. Those invited to submit a proposal were notified on or before April 15, 2023.
This grant supports high-impact clinical research and scientific pilot studies that will ultimately improve the lives of patients with myasthenia gravis and related neuromuscular junction disorders. MGFA funds highly meritorious projects with a maximum of $110,000, over two years. The RFA is open to established and new investigators. Applications in all areas of MG research are accepted from U.S. and international principal investigators. More details about this grant are available in ProposalCentral.
For those invited to submit a proposal: All components must be submitted via MGFA’s grants portal, ProposalCentral, no later than June 1, 2023. A preliminary review to assure compliance with guidelines will be performed, followed by scientific review. Funding notification is expected by August 2023 and funds provided by September 2023.
KEY DATES
Activity
|
Date
|
Call for Proposals Opens
|
Feb. 17, 2023
|
Letter of Intent Deadline
|
April 1, 2023
|
Notification of Invitation to Proceed with Application
|
April 15, 2023
|
Application Deadline
|
June 1, 2023
|
Funding notification
|
August 2023
|
Funding dispersal
|
Sept. 2023
|
Progress Report / Final Study Report
|
To be determined; details stipulated in Notice of Award letter (typically at 1-year and at the end of the grant award period)
|
Contacts for Questions
For technical inquiries such as system access or site navigation related to ProposalCentral, please email pcsupport@altum.com or call 1-800-875-2562 (toll-free US and Canada) or +1-703-964.5840 (Direct Dial International).
More information about how to register and apply using ProposalCentral:
For all other questions, please email MGFA@myasthenia.org.
MGFA Research Grant Agenda and Funding Areas
We support research that will improve the lives of patients with myasthenia gravis and related neuromuscular junction disorders. The committee has identified five broad research priorities:
- Biomarkers: facilitate early diagnosis, predict clinical outcomes and immunosuppressive therapy response and utilize in clinical trials.
- Disease Mechanisms: understand basic mechanisms and self-tolerance loss throughout course of disease.
- Targeted Therapies: develop new therapeutic targets, prevent widespread immunosuppression and off-target side effects, optimize treatment strategies with existing therapies.
- Patient Outcomes: understand the full impact of disease on daily living and patient treatment priorities, understand collateral effects of disease; related medical conditions, side effects and financial impact.
- Pediatric Treatment: identify strategies, safety concerns, and long-term outcomes.
Funding areas include:
- High-Impact Pilot Project Awards: pilot studies leading to new federal, pharmaceutical or private foundation supported investigations
- Transformative Research Awards: focused, innovative investigations that are highly likely to produce fundamental alterations in understanding myasthenia gravis
- Targeted Research and Special Projects Awards: further greater understanding of MG and its impact on quality of life
- Awards to Engage and Support Young Investigators and Clinicians: recognize the importance of good clinical research and encourage young investigators’ involvement in clinical studies
View Past MGFA Research Grant Recipients here.